drugset / Trial / NCT03081494
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This was a phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer. The study assessed primarily the safety and tolerability of PDR001 in combination with regorafenib.
Timeline
- Start
- 2017-06-09
- Primary completion
- 2019-05-07
- Completion
- 2019-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 120 mg | — |
| Subject | Spartalizumab | Monoclonal antibody | 400 mg | — |